T-cell therapy CAR receptor antigen has been recognized as an important achievement in the treatment of cancer, and the researchers are now testing it in other therapeutic areas, including autoimmune diseases.
The researchers report that in two mouse models of lupus treatment of T-cell CAR increased the life expectancy of individuals. In both models, CD19-targeting CAR T-cell depleted CD19 + B-cells and inhibited the disease process.
T-cell therapy CAR represents a new therapeutic approach in which immune cells are collected patient, genetically modified for target recognition (target cancer is a marker associated with a tumor) and multiply. The cells are then re-administered to the patient. They grow in the body and are considered "living medicine".
The drug has shown promising results with rituximab in rheumatoid arthritis and multiple sclerosis, but proved to be ineffective in the treatment of lupus.
Because CD19 is a marker of all B-cells, the researchers hypothesized that CD19-directed T-cell CAR can be effective in depleting B-cells in lupus. Their experimental approach to test the CD19-targeted CAR T-cells in a mouse model of lupus has been closely connected with the standard approach used among cancer patients. Scientists transferred CAR T-cells in a mouse model of lupus and found that survival rates were better.
Michael C. Milone, MD, Associate Professor of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, explained that his research team also studied the use of CD19-specific CAR T cells in the treatment of other diseases in addition to cancer.
Milone said that, although the models used in this study, are generally recognized models in the field of lupus, they all have their disadvantages compared to human diseases.
The results merit further study, agrees Ignacio Sanz, MD, Director of the Division of Rheumatology at Emory University, Atlanta, Georgia.
"The ideal approach CAR-T-cells to autoimmune diseases involves the use of human cells that are targeted to pathogenic B-cells, and at the same time sparing other B-cells - explains Sanz -. Due to the limited knowledge of the antigens that cause the disease and mediate tissue damage, the immediate use of CAR T cells is a universal effect on B cells. the researchers' work really reinforces the idea that the CAR T cells may be effective in the treatment of human autoimmune diseases and should be considered in the human studies. "